[Adrenergic innervation of the myocardium in rats with toxic exposures]

Arkhiv Anatomii, Gistologii I Embriologii
|September 1, 1988
PubMed

Insights

Chronic cadmium and copper exposure causes heart damage, particularly in the left ventricle. Reduced nerve terminals and metabolic shifts in heart muscle correlate with lesion severity, indicating complex cardiotoxicity.

Area of Science:

  • Cardiovascular toxicology
  • Environmental pathology

Background:

  • Chronic exposure to heavy metals like cadmium and copper can induce cardiotoxicity.
  • Understanding the specific mechanisms and pathological changes in the heart muscle is crucial for assessing health risks.

Purpose of the Study:

  • To investigate the cardiotoxic effects of chronic intraperitoneal cadmium and copper salt administration.
  • To correlate histological and metabolic changes in the heart with the degree of muscular tissue lesion.

Main Methods:

  • Chronic intraperitoneal injection of cadmium and copper salts in animal models.
  • Histopathological examination of cardiac ventricles and atria.
  • Assessment of succinate dehydrogenase activity and lipid accumulation in cardiomyocytes.
  • Evaluation of adrenergic fiber changes and vascular integrity.

Main Results:

  • Cardiotoxic effects were observed, with lesion severity inversely related to luminescent nervous terminals.
  • Metabolic shifts included decreased succinate dehydrogenase activity and lipid accumulation in cardiomyocytes.
  • Histopathological findings revealed myocardial dystrophy, capillary stasis, and edema, predominantly in the left ventricle.
  • Cadmium sulfate exposure showed a stronger association between myocardial lesions and vascular disorders, suggesting neurohumoral involvement beyond hypoxia.

Conclusions:

  • Chronic cadmium and copper exposure induces significant cardiotoxicity, affecting myocardial tissue, adrenergic fibers, and vasculature.
  • The observed metabolic and structural changes highlight the complex pathogenesis of metal-induced heart disease.
  • Findings suggest that both hypoxia and neurohumoral factors contribute to cadmium-induced cardiotoxicity.

Related Concept Videos

Adrenergic Receptors (Adrenoceptors): Classification01:27

Adrenergic Receptors (Adrenoceptors): Classification

Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...